Conservative commentator Charlie Kirk shot and killed at Utah event
Investing.com - Deutsche Bank has reduced its price target on Coloplast A/S (CSE:COLOB) to DKK660.00 from DKK708.00 while maintaining a Hold rating on the stock. According to InvestingPro data, the company’s shares are currently trading near their 52-week low of $9.16, with a market capitalization of approximately $22 billion.
The price target reduction follows Coloplast’s Capital Markets Day held last week, where the company outlined its organic sales growth targets through 2030.
Deutsche Bank cited lower-than-expected margin expansion projections as a key factor in its decision to cut the price target, despite Coloplast targeting what the bank called an "attractive organic sales CAGR of 7-8%" until 2030.
The bank expressed concerns about potential impacts from proposed reimbursement changes in the U.S. market, which could lead to price pressure for Coloplast if enacted.
Deutsche Bank also noted additional uncertainties including the pending appointment of a new CEO, recent uneven delivery on targets, and two product recalls as reasons for maintaining its Hold rating, suggesting "more patience is needed until the stock can re-rate again."
In other recent news, RBC Capital has adjusted its price target for Coloplast A/S, raising it to DKK710 from the previous DKK700. The firm maintains a Sector Perform rating on the stock. This adjustment comes in anticipation of Coloplast’s upcoming Capital Markets Day, where the company is expected to share insights into its mid-term financial expectations, particularly concerning innovation. These developments are part of the latest updates for investors.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.